Cellectis Reports Q3 2026 Revenue of $19.89 Million and GAAP EPS Loss of $1.00
Cellectis S.A. (CLLS) has released its financial results for the third quarter of 2026, reporting a GAAP earnings per share (EPS) loss of $1.00. The company generated $19.89 million in revenue during this period. The report comes amid a significant strategic pivot toward in-vivo gene editing technologies. While management is focusing on transforming the company's pipeline, market sentiment has been tempered by recent analyst actions, including a downgrade from Citizens following the announcement of this shift in focus.
Tickers: $CLLS
Topics: earnings report EPS gene editing revenue strategic transformation